A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men
A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men
This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
Inclusion Criteria:
• Osteoporosis as defined by very low bone mineral density in the hip and spine or low bone mineral density in the hip combined with presence of 1-3 mild or moderate fractures of the vertebrae
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Geelong-VIC, Australia
Maroochydore-QLD, Australia
Randwick-NSW, Australia
Siena-SI, Italy
Rosebank-Johannesburg, South Africa
Western Cape, South Africa
Middx, United Kingdom
Reading-Berkshire, United Kingdom